北極星藥業-KY News Releases

[Polaris Group] Correction of Endorsement Guarantee Disclosure for March 2026

Polaris Group has issued a correction regarding the endorsement guarantee balance of its subsidiary,… · 2026-05-27

【Polaris Pharmaceuticals-KY】Adjustment of Organizational Structure and Manpower for US Subsidiaries

Polaris Pharmaceuticals announced on May 25, 2026, that it is adjusting the organizational structure… · 2026-05-25

【Polaris Pharmaceuticals-KY】Suspension of Phase III Clinical Trial for ADI-PEG 20 in Leiomyosarcoma (LMS)

Polaris Pharmaceuticals announced on May 25, 2026, that it is suspending its Phase III clinical tria… · 2026-05-25

【Polaris Pharmaceuticals-KY】Voluntary Withdrawal of BLA for Pegargiminase (ADI-PEG 20) for Malignant Pleural Mesothelioma

Polaris Pharmaceuticals announced on May 25, 2026, that it will voluntarily withdraw its BLA for Peg… · 2026-05-25

[Polaris Pharmaceuticals KY] Announcement regarding the convener of the Remuneration Committee

Polaris Pharmaceuticals KY announced on May 25, 2026, the re-election of the convener of its Remuner… · 2026-05-25

[Polaris Pharmaceuticals-KY] Announcement Regarding the Change of Audit Committee Convener

Polaris Pharmaceuticals-KY announced a change in the Audit Committee convener. Following the expirat… · 2026-05-25

[Polaris Group] Announcement Regarding the Change of Director at Subsidiary, LianYang Pharma

Polaris Group announced a change of director at its subsidiary, LianYang Pharma. Mr. Chen Hong-wen h… · 2026-05-25

[Polaris Group] Announcement on the Change of Director at Subsidiary Lumosa Therapeutics

Lumosa Therapeutics, a subsidiary of Polaris Group, announced a change of director effective May 25,… · 2026-05-25

[Polaris Group] Announcement Regarding Change of CEO

Polaris Group announced a change in CEO effective May 25, 115, with Chairman Chen Hsien-che serving … · 2026-05-25

[Polaris Group] Announcement of Completion of Payment and Capital Increase Reference Date for the 114th Second Private Placement of Common Shares

Polaris Group has completed the private placement of common shares, raising NT$628.2 million through… · 2026-05-22

[Polaris Group] Notice regarding correction of shareholding during board election

Polaris Group announced a correction on May 21, 2026, regarding the shareholding numbers during the … · 2026-05-21

[Polaris Group-KY] Announcement of full re-election of directors (including independent directors) at the 2026 Annual General Meeting

Polaris Group conducted a full board re-election, re-appointing Chairman Chen Xian-Zhe and bringing … · 2026-05-15

Polaris Group Announces Key Resolutions of the 2025 Annual Shareholders Meeting

Polaris Group held its annual shareholders meeting, approving financial reports and deciding on boar… · 2026-05-15

[Polaris Group-KY] Announcement of AGM resolution to lift non-compete restrictions on new directors

Polaris Group's AGM approved lifting the non-compete restrictions for Chairman Chen Xian-Zhe and cor… · 2026-05-15

[Polaris Group-KY] Announcement of Audit Committee members

Polaris Group announced its new Audit Committee members, comprising independent directors Zhao Ying-… · 2026-05-15

[Polaris Group-KY] Announcement of full re-election of directors (including independent directors) at the 2026 Annual General Meeting

Polaris Group conducted a full board re-election, re-appointing Chairman Chen Xian-Zhe and bringing … · 2026-05-15

[Polaris Group-KY] Announcement of the Board of Directors electing the Chairman

Polaris Group's board of directors has re-elected Chen Xian-Zhe as Chairman following the expiration… · 2026-05-15

[Polaris Group-KY] Announcement of the Board of Directors' Resolution to Appoint Members of the Compensation Committee

Polaris Group-KY has re-elected its compensation committee members following a board resolution. Thi… · 2026-05-15

[Polaris Group-KY] Announcement to Creditors Regarding AGM Resolution to Reduce Capital to Cover Losses

Polaris Group's AGM approved a 50% capital reduction (approx. NT$4.3 billion) to offset accumulated … · 2026-05-15

Polaris Group Announces Key Resolutions of the 2025 Annual Shareholders Meeting

Polaris Group held its annual shareholders meeting, approving financial reports and deciding on boar… · 2026-05-15

[Polaris Group-KY] Announcement of AGM resolution to lift non-compete restrictions on new directors

Polaris Group's AGM approved lifting the non-compete restrictions for Chairman Chen Xian-Zhe and cor… · 2026-05-15

[Polaris Group-KY] Announcement of Audit Committee members

Polaris Group announced its new Audit Committee members, comprising independent directors Zhao Ying-… · 2026-05-15

[Polaris Group-KY] Announcement of the Board of Directors electing the Chairman

Polaris Group's board of directors has re-elected Chen Xian-Zhe as Chairman following the expiration… · 2026-05-15

[Polaris Group-KY] Announcement of the Board of Directors' Resolution to Appoint Members of the Compensation Committee

Polaris Group-KY has re-elected its compensation committee members following a board resolution. Thi… · 2026-05-15

[Polaris Group-KY] Announcement to Creditors Regarding AGM Resolution to Reduce Capital to Cover Losses

Polaris Group's AGM approved a 50% capital reduction (approx. NT$4.3 billion) to offset accumulated … · 2026-05-15

[Polaris Pharmaceuticals-KY] Announcement of Board Resolution on Pricing Matters for Cash Increase Private Placement of Common Stock

Polaris Pharmaceuticals-KY announced its board of directors has resolved to conduct a private placem… · 2026-05-12

[Polaris Pharmaceuticals-KY] Announcement of Board Resolution on Pricing Matters for Cash Increase Private Placement of Common Stock

Polaris Pharmaceuticals-KY announced its board of directors has resolved to conduct a private placem… · 2026-05-12

Polaris Pharmaceutical-KY Announces Endorsement and Guarantee Reaches Public Offering Company Fund Lending and Endorsement/Guarantee Handling Standards Article 25, Paragraph 1, Item 3

Polaris Pharmaceutical-KY announced an increase in its endorsement and guarantee for its wholly-owne… · 2026-05-12

Polaris Pharmaceutical-KY Announces Board Approval of Consolidated Financial Report for Q1 FY2026

Polaris Pharmaceutical-KY announced that its consolidated financial report for the first quarter of … · 2026-05-12

Polaris Pharmaceutical-KY Announces Board Approval of Consolidated Financial Report for Q1 FY2026

Polaris Pharmaceutical-KY announced that its consolidated financial report for the first quarter of … · 2026-05-12

Polaris Pharmaceutical-KY Announces Endorsement and Guarantee Reaches Public Offering Company Fund Lending and Endorsement/Guarantee Handling Standards Article 25, Paragraph 1, Item 3

Polaris Pharmaceutical-KY announced an increase in its endorsement and guarantee for its wholly-owne… · 2026-05-12

[Polaris Pharmaceuticals-KY] Announcement of the Scheduled Board Meeting Date for the Company's First Quarter 2026 Consolidated Financial Report

Polaris Pharmaceuticals-KY announced that its board meeting to report the first quarter 2026 consoli… · 2026-05-04

[Polaris Pharmaceuticals-KY] Announcement of the Scheduled Board Meeting Date for the Company's First Quarter 2026 Consolidated Financial Report

Polaris Pharmaceuticals-KY announced that its board meeting to report the first quarter 2026 consoli… · 2026-05-04

[Polaris Biopharma] May 2026 Revenue Reaches NT$ 1.6M (+248.7% YoY)

Biotech company Polaris Biopharma announced its May 2026 revenue of NT$ 1,601 thousand (approx. NT$ … · 2026-05-01

Polaris Pharmaceuticals-KY: Announcement of commitments made by the company during its stock listing application and subsequent execution status

Polaris Pharmaceuticals-KY announced on April 7, 2026, the commitments made during its stock listing… · 2026-04-07

Polaris Pharmaceuticals-KY: Announcement of commitments made by the company during its stock listing application and subsequent execution status

Polaris Pharmaceuticals-KY announced on April 7, 2026, the commitments made during its stock listing… · 2026-04-07

Polaris Pharmaceuticals-KY: Announcement of commitments made by the company during its stock listing application and subsequent execution status

Polaris Pharmaceuticals-KY announced on April 7, 2026, the commitments made during its stock listing… · 2026-04-07

[Stellar Pharmaceuticals-KY] April 2026 Revenue 0.02 Billion (Year-on-Year Decrease of -57.1%)

Stellar Pharmaceuticals-KY announced its April 2026 revenue of NT$1.668 million, a significant decre… · 2026-04-01

[Stellar Pharmaceuticals-KY] April 2026 Revenue 0.02 Billion (Year-on-Year Decrease of -57.1%)

Stellar Pharmaceuticals-KY announced its April 2026 revenue of NT$1.668 million, a significant decre… · 2026-04-01

[Polaris Group] March 2026 Revenue NT$2M (YoY -59.7%)

Biopharmaceutical company Polaris Group (code: 6550) reported monthly revenue of NT$1.57 million for… · 2026-03-01

[Polaris Group] March 2026 Revenue NT$2M (YoY -59.7%)

Biopharmaceutical company Polaris Group (code: 6550) reported monthly revenue of NT$1.57 million for… · 2026-03-01

【Polaris Group-KY】February 2026 Revenue Reaches NT$17 Million, a 322.9% YoY Increase

Polaris Group-KY announced its February 2026 revenue reached NT$17 million, a significant year-over-… · 2026-02-01

【Polaris Group-KY】February 2026 Revenue Reaches NT$17 Million, a 322.9% YoY Increase

Polaris Group-KY announced its February 2026 revenue reached NT$17 million, a significant year-over-… · 2026-02-01